Company intelligence / Profile preview

9Bio Therapeutics

Quebec City, Quebec, Canada9bio.ca ↗

Ownership: Private
Development stage: Other

Overview

All pipeline programs are in discovery or preclinical development. The company has received multi-year federal funding to advance its lead candidates through rigorous preclinical safety and efficacy studies required for regulatory approval of clinical testing. No human clinical results have been reported yet.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugatesEngineered cytokinesProtein-based therapeuticsCAR T cellsLigand/receptor mimetics
Industry: Biotech

Drug pipeline

2 assets

9B06

Preclinical

1 more asset in the full pipeline.

Partnerships

National Research Council Canada (NRC) – collaboration on ADC programTransBIOTech – preclinical research partnership supported by NSERC grantVega BioImaging – companion diagnostic co-development for oncology therapy; CQDM-backed project for head, neck, metastatic breast cancers

Beyond the preview

Go deeper on 9Bio Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 9Bio Therapeutics.